# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001213900-25-088792
Filing Date
2025-09-18
Accepted
2025-09-18 08:56:13
Documents
38
Period of Report
2025-09-18
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | CURRENT REPORT | ea0257842-8k_nektar.htm iXBRL | 8-K | 26793
2 | SLIDES TITLED "EFFICACY AND SAFETY OF REZPEGALDESLEUKIN, A SELECTIVE REGULATORY | ea025784201ex99-1_nektar.htm | EX-99.1 | 37065
3 | PRESS RELEASE TITLED "NEKTAR PRESENTS NEW DATA FROM REZOLVE-AD PHASE 2B STUDY FO | ea025784201ex99-2_nektar.htm | EX-99.2 | 60175
4 | GRAPHIC | ex99-1_001.jpg | GRAPHIC | 1409674
5 | GRAPHIC | ex99-1_002.jpg | GRAPHIC | 595710
6 | GRAPHIC | ex99-1_003.jpg | GRAPHIC | 481551
7 | GRAPHIC | ex99-1_004.jpg | GRAPHIC | 550255
8 | GRAPHIC | ex99-1_005.jpg | GRAPHIC | 799390
9 | GRAPHIC | ex99-1_006.jpg | GRAPHIC | 597027
10 | GRAPHIC | ex99-1_007.jpg | GRAPHIC | 1008632
11 | GRAPHIC | ex99-1_008.jpg | GRAPHIC | 520718
12 | GRAPHIC | ex99-1_009.jpg | GRAPHIC | 536169
13 | GRAPHIC | ex99-1_010.jpg | GRAPHIC | 390958
14 | GRAPHIC | ex99-1_011.jpg | GRAPHIC | 421229
15 | GRAPHIC | ex99-1_012.jpg | GRAPHIC | 432895
16 | GRAPHIC | ex99-1_013.jpg | GRAPHIC | 513391
17 | GRAPHIC | ex99-1_014.jpg | GRAPHIC | 556599
18 | GRAPHIC | ex99-1_015.jpg | GRAPHIC | 437261
19 | GRAPHIC | ex99-1_016.jpg | GRAPHIC | 496876
20 | GRAPHIC | ex99-1_017.jpg | GRAPHIC | 528967
21 | GRAPHIC | ex99-1_018.jpg | GRAPHIC | 612819
22 | GRAPHIC | ex99-1_019.jpg | GRAPHIC | 747607
23 | GRAPHIC | ex99-1_020.jpg | GRAPHIC | 323028
24 | GRAPHIC | ex99-1_021.jpg | GRAPHIC | 514139
25 | GRAPHIC | ex99-1_022.jpg | GRAPHIC | 475828
26 | GRAPHIC | ex99-1_023.jpg | GRAPHIC | 320679
27 | GRAPHIC | ex99-2_001.jpg | GRAPHIC | 13138
| Complete submission text file | 0001213900-25-088792.txt |  | 18608870

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
28 | XBRL SCHEMA FILE | nktr-20250918.xsd | EX-101.SCH | 3008
29 | XBRL LABEL FILE | nktr-20250918_lab.xml | EX-101.LAB | 34239
30 | XBRL PRESENTATION FILE | nktr-20250918_pre.xml | EX-101.PRE | 22354
40 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0257842-8k_nektar_htm.xml | XML | 3565

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 251321853
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)